Resverlogix Corp. Company Profile (TSE:RVX)

About Resverlogix Corp. (TSE:RVX)

Resverlogix Corp. logoResverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: TSE:RVX
  • CUSIP: N/A
  • Web: www.resverlogix.com/
Capitalization:
  • Market Cap: C$163.91 million
  • Outstanding Shares: 114,624,000
Average Prices:
  • 50 Day Moving Avg: C$1.49
  • 200 Day Moving Avg: C$1.65
  • 52 Week Range: C$1.23 - C$2.41
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: C($1.00) per share
  • Price / Book: -1.43
Profitability:
  • EBITDA: ($35,430,000.00)
  • Return on Assets: -602.93%
Misc:
  • Average Volume: 34,065 shs.
  • Short Ratio: 4.05
 

Frequently Asked Questions for Resverlogix Corp. (TSE:RVX)

What is Resverlogix Corp.'s stock symbol?

Resverlogix Corp. trades on the Tornton Stock Exchange (TSX) under the ticker symbol "RVX."

When will Resverlogix Corp. make its next earnings announcement?

Resverlogix Corp. is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Resverlogix Corp..

Who are some of Resverlogix Corp.'s key competitors?

Who are Resverlogix Corp.'s key executives?

Resverlogix Corp.'s management team includes the folowing people:

  • Donald J. McCaffrey, Chairman of the Board, President, Chief Executive Officer, Secretary
  • A. Brad Cann, Chief Financial Officer
  • Jan O. Johansson M.D. Ph.D., Senior Vice President - Medical Affairs
  • Kenneth Lebioda, Senior Vice President - Business & Corporate Development
  • Michael T. Sweeney M.D., Senior Vice President - Clinical Development
  • Norman Wong M.D., Chief Scientific Officer
  • Eldon R. Smith M.D., Lead Director
  • Norma K. Biln, Director
  • Shawn Lu, Director
  • Kelly B. McNeill, Independent Director

How do I buy Resverlogix Corp. stock?

Shares of Resverlogix Corp. and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Resverlogix Corp.'s stock price today?

One share of Resverlogix Corp. stock can currently be purchased for approximately C$1.43.


MarketBeat Community Rating for Resverlogix Corp. (TSE RVX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  43
MarketBeat's community ratings are surveys of what our community members think about Resverlogix Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Resverlogix Corp. (TSE:RVX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Resverlogix Corp. (TSE:RVX)
Price Target History for Resverlogix Corp. (TSE:RVX)
Analysts' Ratings History for Resverlogix Corp. (TSE:RVX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Resverlogix Corp. (TSE:RVX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Resverlogix Corp. (TSE:RVX)
2017 EPS Consensus Estimate: ($0.18)
2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20171($0.06)($0.06)($0.06)
Q1 20181($0.14)($0.14)($0.14)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.13)($0.13)($0.13)
Q4 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Resverlogix Corp. (TSE:RVX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Resverlogix Corp. (TSE:RVX)
Insider Trades by Quarter for Resverlogix Corp. (TSE:RVX)
Insider Trades by Quarter for Resverlogix Corp. (TSE:RVX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/29/2016Michael SweeneyInsiderSell4,900C$0.96C$4,691.75
3/28/2016Michael SweeneyInsiderSell5,000C$0.98C$4,881.50
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Resverlogix Corp. (TSE:RVX)
Latest Headlines for Resverlogix Corp. (TSE:RVX)
Source:
DateHeadline
globenewswire.com logoResverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
globenewswire.com - October 14 at 7:32 AM
globenewswire.com logoResverlogix Announces $87 Million Private Placement with Shenzhen Hepalink
globenewswire.com - October 14 at 7:32 AM
finance.yahoo.com logoHealthcare Stocks: Is Now The Time To Buy Resverlogix Corp (TSX:RVX)?
finance.yahoo.com - October 12 at 3:21 PM
finance.yahoo.com logoResverlogix Announces Annual and Special Meeting of Shareholders
finance.yahoo.com - October 3 at 11:55 AM
finance.yahoo.com logoResverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
finance.yahoo.com - September 13 at 9:45 PM
finance.yahoo.com logoResverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
finance.yahoo.com - September 5 at 7:41 AM
finance.yahoo.com logoSuccessful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
finance.yahoo.com - August 30 at 8:46 AM
reuters.com logoBRIEF-Resverlogix announces extension of maturity date of loan and expression of interest on strategic transaction
www.reuters.com - August 29 at 7:29 AM
finance.yahoo.com logoResverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
finance.yahoo.com - August 29 at 7:29 AM
finance.yahoo.com logoResverlogix (RVX) Reports Fiscal Year 2017 Results
finance.yahoo.com - August 14 at 3:36 PM
americanbankingnews.com logoBrokers Issue Forecasts for Resverlogix Corp.'s Q1 2018 Earnings (TSE:RVX)
www.americanbankingnews.com - August 3 at 1:58 PM
finance.yahoo.com logoCORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoIIROC Trading Halt - RVX
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoResverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoIIROC Trade Resumption - Resverlogix Corp.
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoIIROC Trade Resumption - RVX
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoResverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
finance.yahoo.com - July 26 at 7:01 AM
finance.yahoo.com logoResverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
finance.yahoo.com - July 11 at 7:21 AM
finance.yahoo.com logoResverlogix Randomizes First Patient in Taiwan/mainland China Portion of the Phase 3 BETonMACE Clinical Trial
finance.yahoo.com - July 11 at 7:21 AM
finance.yahoo.com logoDaily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
finance.yahoo.com - July 5 at 10:19 AM
prnewswire.com logoResverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 - PR Newswire (press release)
www.prnewswire.com - June 5 at 7:09 AM
prnewswire.com logoResverlogix celebra un simposio centrado en epigenética en el ERA-EDTA Congress de Madrid, España - PR Newswire (Comunicado de prensa)
www.prnewswire.com - June 1 at 10:18 PM
prnewswire.com logoResverlogix recibe la aprobación de Health Canada para proceder con el ensayo clínico en enfermedad de Fabry - PR Newswire (Comunicado de prensa)
www.prnewswire.com - June 1 at 10:18 PM
prnewswire.com logoResverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead ... - PR Newswire (press release)
www.prnewswire.com - June 1 at 10:18 PM
prnewswire.com logoReciente publicación y solicitud de patente de apabetalone apoya su desarrollo continuado y éxito - PR Newswire (Comunicado de prensa)
www.prnewswire.com - May 23 at 7:01 PM
prnewswire.com logoResverlogix recibe aprobación de la FDA para un ensayo clínico de Apabetalone - PR Newswire (Comunicado de prensa)
www.prnewswire.com - May 17 at 7:35 PM
prnewswire.com logoResverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of ... - PR Newswire (press release)
www.prnewswire.com - March 18 at 8:18 AM
prnewswire.com logoResverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis ... - PR Newswire (press release)
www.prnewswire.com - February 24 at 5:13 AM
prnewswire.com logoResverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments - PR Newswire (press release)
www.prnewswire.com - January 24 at 8:00 AM
prnewswire.com logoResverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA - PR Newswire (press release)
www.prnewswire.com - January 7 at 2:11 AM
prnewswire.com logoResverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders - PR Newswire (press release)
www.prnewswire.com - December 16 at 2:49 AM
reuters.com logoProfile: Resverlogix Corp (RVX.TO)
www.reuters.com - December 13 at 12:48 AM

Social

Chart

Resverlogix Corp. (RVX) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.